Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 5,613 shares, a growth of 205.1% from the September 30th total of 1,840 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 8,301 shares, the short-interest ratio is currently 0.7 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Addex Therapeutics
Addex Therapeutics Price Performance
Addex Therapeutics stock traded up $0.13 during trading on Friday, reaching $3.06. 1,905 shares of the company were exchanged, compared to its average volume of 52,967. The company has a market capitalization of $3.77 million, a P/E ratio of -0.52 and a beta of 1.52. The stock’s 50 day simple moving average is $3.37 and its two-hundred day simple moving average is $5.84. Addex Therapeutics has a 52-week low of $2.56 and a 52-week high of $10.43.
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last released its quarterly earnings data on Friday, September 25th. The company reported ($1.48) EPS for the quarter. The company had revenue of $0.01 million during the quarter.
Addex Therapeutics Company Profile
Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company focuses on discovering and developing orally available small-molecule therapies that target G protein-coupled receptors (GPCRs), an important class of proteins involved in signaling throughout the nervous system.
Addex’s approach centers on allosteric modulation, which aims to influence receptor activity at sites distinct from where natural signaling molecules bind.
Further Reading
- Five stocks we like better than Addex Therapeutics
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
